Daiichi Sankyo Company, Limited
Stock Price Chart
2026/03/04 UpdatedPrice Trend
2026/03/04 UpdatedPrice & Trading Details
2026/03/04 UpdatedPRICE
TRADING
Analyst Recommendations 16 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
EuroPacific Growth Fund-EUPAC Fund
|
45.7M | -9.61% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
26.7M | +0.03% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
20.1M | -16.80% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
17.1M | +2.72% | |
|
CAPITAL WORLD GROWTH & INCOME FUND
|
15.2M | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
12.2M | -0.20% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
14.8K | -3.38% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥69 | +15.0% |
| 2024 | ¥60 | +71.4% |
| 2023 | ¥35 | +22.8% |
| 2022 | ¥29 | +5.6% |
| 2021 | ¥27 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,044,892M | ¥1,278,478M | ¥1,601,688M | ¥1,886,256M |
| Gross Profit | ¥691,491M | ¥914,952M | ¥1,186,366M | ¥1,470,458M |
| Operating Income | ¥73,027M | ¥120,582M | ¥211,589M | ¥331,925M |
| Pretax Income | ¥79,269M | ¥135,334M | ¥243,260M | ¥367,485M |
| Net Income | ¥66,972M | ¥109,188M | ¥200,731M | ¥295,756M |
| EPS | ¥34.91 | ¥56.91 | ¥104.62 | ¥155.87 |
| Operating Margin | 6.99% | 9.43% | 13.21% | 17.60% |
| Balance Sheet | ||||
| Total Assets | ¥2,221,402M | ¥2,508,889M | ¥3,461,135M | ¥3,456,119M |
| Total Equity | ¥1,350,872M | ¥1,445,854M | ¥1,688,173M | ¥1,623,416M |
| Total Liabilities | ¥870,530M | ¥1,063,035M | ¥1,772,962M | ¥1,832,703M |
| Cash | ¥662,477M | ¥441,921M | ¥647,180M | ¥639,838M |
| Interest-bearing Debt | ¥163,461M | ¥143,088M | ¥101,713M | ¥101,332M |
| Equity Ratio | 60.81% | 57.63% | 48.78% | 46.97% |
| D/E Ratio | 0.12 | 0.10 | 0.06 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥139,226M | ¥114,514M | ¥599,258M | ¥53,842M |
| Investing CF | ¥212,339M | -¥257,782M | -¥282,636M | ¥334,170M |
| Financing CF | -¥86,231M | -¥89,594M | -¥123,564M | -¥377,769M |
| Free CF | ¥62,544M | ¥47,148M | ¥476,467M | -¥134,030M |
| Efficiency | ||||
| ROE | 4.96% | 7.55% | 11.89% | 18.22% |
| ROA | 3.01% | 4.35% | 5.80% | 8.56% |
Latest IR Information
-
Notice Regarding Status of Treasury Stock Acquisition
From February 1 to February 28, 2026, the Company acquired 14,198,900 shares of common stock for ¥41,849,992,950. The total cumulative shares acquired amount to 17,602,500 shares, with an acquisition cost of ¥51,849,239,900.
Read more -
Notification Regarding Changes to Representative Director and Selection of Director and Auditor Candidates
Change of representative director effective June 22, 2026. Mr. Takashi Matsumoto is scheduled to assume the new representative director role. Selection of director and auditor candidates has also been conducted to enhance diversity and expertise.
Read more -
Notice Regarding the Status of Treasury Stock Acquisitions
From January 1 to January 31, 2026, Daiichi Sankyo Company, Limited acquired 3,403,600 shares of the Company’s common stock at a total cost of 9,999,246,950 yen.
Read more -
Supplementary Financial Information (FY2025 Third Quarter Financial Results)
For the cumulative third quarter of FY2025, revenue was 1,533.5 billion yen (YoY +12.1%), operating income was 233.8 billion yen (YoY -5.9%), and net income attributable to owners of parent was 217.4 billion yen (YoY +4.2%).
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥4,924
Rating Score: 1.38 (Based on 16 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. The company has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
